Based on ACR rules, allopurinol is strongly encouraged as a primary-line urate-reducing medication. Genetic screening is usually recommended (for a variant referred to as HLA B*5801) before beginning allopurinol because the carriers of this gene are at an increased risk of a intense allergic reaction.Dos akan dinaikkan secara beransur-ansur sehingg